Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.

Alifrangis L, Schoemaker R, Skartved NJ, Hald R, Montagut C, Kopetz S, Tabernero J, Kragh M, Wade JR.

J Pharmacokinet Pharmacodyn. 2019 Nov 2. doi: 10.1007/s10928-019-09663-2. [Epub ahead of print]

PMID:
31679083
2.

Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.

Poulsen TT, Grandal MM, Skartved NJØ, Hald R, Alifrangis L, Koefoed K, Lindsted T, Fröhlich C, Pollmann SE, Eriksen KW, Dahlman A, Jacobsen HJ, Bouquin T, Pedersen MW, Horak ID, Lantto J, Kragh M.

Clin Cancer Res. 2017 Oct 1;23(19):5923-5935. doi: 10.1158/1078-0432.CCR-17-0782. Epub 2017 Jul 5.

3.

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J.

Cancer Discov. 2015 Jun;5(6):598-609. doi: 10.1158/2159-8290.CD-14-1432. Epub 2015 May 11.

4.

Dance injuries.

Hald RD.

Prim Care. 1992 Jun;19(2):393-411. Review.

PMID:
1609011
5.

Supplemental Content

Support Center